HCM
NEUTRALHUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
The biopharmaceutical company has announced the publication of positive Phase III results for its lung cancer treatment combination in a leading medical journal.
HUTCHMED (China) Limited
225.00GBX
-3.23%
Market Cap
1.93B
Volume
2.36k
9% of avg
P/E Ratio
4437.10
EPS (TTM)
0.05
Beta
0.5
Day Range
225.00p - 239.00p
52 Week Range
185.50p225.00p292.00p
225.00p
Upcoming Events
Q2 2026
Resubmission of the new drug application for second-line immune thrombocytopenia (ITP)
High Impact Event
H1 2026
Topline results from the SAFFRON study expected
High Impact Event
HCM
NEUTRALHUTCHMED Announces Positive Topline Results of Phase III Trial for Warm Antibody Autoimmune Hemolytic Anemia
The biopharmaceutical company reports positive topline results from a Phase III trial of its drug candidate sovleplenib for the treatment of a rare blood disorder.
HCM
NEUTRALHUTCHMED Initiates Phase III Trial of Surufatinib and Camrelizumab Combination for Pancreatic Cancer
The biopharmaceutical company has initiated the Phase III part of a trial evaluating a combination therapy for the treatment of metastatic pancreatic cancer.
HCM
NEUTRALHUTCHMED Announces NDA Acceptance in China for Savolitinib in Gastric Cancer
The healthcare company announces that its NDA for savolitinib to treat gastric cancer patients with MET amplification has been accepted and granted priority review by the China NMPA.
HCM
NEUTRALHUTCHMED Announces NDA Acceptance in China for Fanregratinib
The healthcare company announces that its NDA for fanregratinib has been accepted and granted priority review by the China NMPA.
HCM
NEUTRALHUTCHMED Initiates Development of ATTC Candidate
The biopharmaceutical company has initiated global clinical development of a new ATTC candidate for treating solid tumors.
HCM
GOODHUTCHMED Announces Expanded NRDL and Commercial Insurance Drug List Coverage in China
The healthcare company has secured expanded coverage for its key products in China's drug reimbursement and insurance schemes, boosting patient access.
HCM
NEUTRALHUTCHMED Highlights Data at ESMO and ASH
The biopharmaceutical company is presenting data on several of its drug candidates at upcoming medical conferences.
HCM
NEUTRALHUTCHMED Completes Enrollment for SAFFRON Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Lung Cancer
The biopharmaceutical company has completed enrollment for a global Phase III trial studying a combination therapy for certain lung cancer patients.
HCM
NEUTRALHUTCHMED Unveils Innovative ATTC Platform and Highlights Pipeline Progress
The biopharmaceutical company unveils its new ATTC platform for precision oncology and provides updates on the advancement of its late-stage drug pipeline.